MDS-482 Impact of magrolimab in combination with azacitidine on red blood cells (RBCs) in patients with higher-risk myelodysplastic syndromes (HR MDS) (Clinical Lymphoma Myeloma and Leukemia, 2022)

(untitled) - Chen, J; Johnson, L; McKenna, K; Choi, T; Duan, J; Feng, D; Tsai, J; Garcia-Martin, N; Sompalli, K; Maute, R; Vyas, P; Majeti, R; et al.